

Supplementary Online Content

Rahma OE, Yothers G, Hong TS, et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. *JAMA Oncol*. Published online July 1, 2021. doi:10.1001/jamaoncol.2021.1683

eTable. Immune-Related Adverse Events During and After Chemoradiation: NRG Oncology GI002

eFigure. Study Schema: NRG Oncology GI002

This supplementary material has been provided by the authors to give readers additional information about their work.


eTable. Immune-Related Adverse Events During and After Chemoradiotherapy: NRG Oncology GI002

System Organ Class/Term	RT + Capecitabine (n=83)				RT + Capecitabine + Pembrolizumab (n=81)			
	n and (%) of Pts by Grade				n and (%) of Pts by Grade			
	2	3	4	5	2	3	4	5
Overall Highest Grade	19	8	0	0	32	3	0	0
	(22.9)	(9.6)	(0.0)	(0.0)	(39.5)	(3.7)	(0.0)	(0.0)
ENDOCRINE DISORDERS	1	0	0	0	10	1	0	0
	(1.2)	(0.0)	(0.0)	(0.0)	(12.3)	(1.2)	(0.0)	(0.0)
Hyperthyroidism	0	0	0	0	5	0	0	0
	(0.0)	(0.0)	(0.0)	(0.0)	(6.2)	(0.0)	(0.0)	(0.0)
Hypothyroidism	1	0	0	0	7	1	0	0
	(1.2)	(0.0)	(0.0)	(0.0)	(8.6)	(1.2)	(0.0)	(0.0)
GASTROINTESTINAL DISORDERS	14	7	0	0	19	2	0	0
	(16.9)	(8.4)	(0.0)	(0.0)	(23.5)	(2.5)	(0.0)	(0.0)
Colitis	1	0	0	0	2	0	0	0
	(1.2)	(0.0)	(0.0)	(0.0)	(2.5)	(0.0)	(0.0)	(0.0)
Diarrhea	13	7	0	0	18	2	0	0
	(15.7)	(8.4)	(0.0)	(0.0)	(22.2)	(2.5)	(0.0)	(0.0)
Enterocolitis	1	0	0	0	0	0	0	0
	(1.2)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
HEPATOBIILIARY	2	1	0	0	5	0	0	0
	(2.4)	(1.2)	(0.0)	(0.0)	(6.2)	(0.0)	(0.0)	(0.0)
Alanine aminotransferase increased	1	0	0	0	2	0	0	0
	(1.2)	(0.0)	(0.0)	(0.0)	(2.5)	(0.0)	(0.0)	(0.0)
Alkaline phosphatase increased	0	0	0	0	1	0	0	0
	(0.0)	(0.0)	(0.0)	(0.0)	(1.2)	(0.0)	(0.0)	(0.0)
Aspartate aminotransferase increased	0	1	0	0	2	0	0	0
	(0.0)	(1.2)	(0.0)	(0.0)	(2.5)	(0.0)	(0.0)	(0.0)
Blood bilirubin increased	1	0	0	0	3	0	0	0
	(1.2)	(0.0)	(0.0)	(0.0)	(3.7)	(0.0)	(0.0)	(0.0)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	1	0	0	0	5	0	0	0
	(1.2)	(0.0)	(0.0)	(0.0)	(6.2)	(0.0)	(0.0)	(0.0)

System Organ Class/Term	RT + Capecitabine (n=83)				RT + Capecitabine + Pembrolizumab (n=81)			
	n and (%) of Pts by Grade				n and (%) of Pts by Grade			
	2	3	4	5	2	3	4	5
Arthralgia	0	0	0	0	4	0	0	0
	(0.0)	(0.0)	(0.0)	(0.0)	(4.9)	(0.0)	(0.0)	(0.0)
Myalgia	1	0	0	0	2	0	0	0
	(1.2)	(0.0)	(0.0)	(0.0)	(2.5)	(0.0)	(0.0)	(0.0)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	2	0	0	0	3	0	0	0
	(2.4)	(0.0)	(0.0)	(0.0)	(3.7)	(0.0)	(0.0)	(0.0)
Pruritus	1	0	0	0	1	0	0	0
	(1.2)	(0.0)	(0.0)	(0.0)	(1.2)	(0.0)	(0.0)	(0.0)
Rash maculo-papular	2	0	0	0	2	0	0	0
	(2.4)	(0.0)	(0.0)	(0.0)	(2.5)	(0.0)	(0.0)	(0.0)

Abbreviations: RT, radiotherapy. Adverse events were graded with CTCAE version 5.

eFigure. Study Schema: NRG Oncology GI002



^a**modified FOLFOX6 regimen:** Oxaliplatin 85mg/m² IV Day 1 + leucovorin 400mg/m² IV Day 1 + 5-FU 400mg/m² IV bolus followed by 5-FU 2400 mg/m² continuous infusion over 46 hrs every 2 wks for 8 cycles.

^b**RT starts 3-4 weeks following last dose of mFOLFOX6.**
4500 cGy in 25 fractions over 5 wks + 540 cGy boost in 3 fractions.

^cSurgery performed 8-12 wks following last dose of radiotherapy.